2010 CVM News: Unique collaboration holds potential for life-saving drugs for tuberculosis

dc.contributor.author	Office of Communications
dc.date.accessioned	2018-08-23T18:18:44Z
dc.date.available	2018-08-23T18:18:44Z
dc.date.issued	2010-10-07
dc.description.abstract	This news item is about: Dr. David Russell, of Cornell’s College of Veterinary Medicine, has established a paradigm-shifting collaborative relationship with Vertex Pharmaceuticals, of Cambridge, Mass., opening a door for novel tuberculosis (TB) drug discovery. Dr. Russell’s long-term goal is to help the many millions around the world who suffer from tuberculosis, the disease caused by Mycobacterium tuberculosis, by finding new compounds that can reduce the treatment time and also be effective against drug resistant TB. The collaboration will provide access to the pharmaceutical company’s drug library, comprised of hundreds of thousands of compounds. Many of these compounds have not yet been screened for anti-tuberculosis activity.
dc.identifier.uri	https://hdl.handle.net/1813/58439
dc.language.iso	en_US
dc.publisher	Cornell University, College of Veterinary Medicine
dc.subject	Cornell University. College of Veterinary Medicine -- Periodicals.; Russell, David G.
dc.title	2010 CVM News: Unique collaboration holds potential for life-saving drugs for tuberculosis
dc.type	article

Files

Now showing 1 - 1 of 1